Abi Siva, Associate Professor and Director of Medical Oncology at MUSC Health Hematology Oncology at Hollings Cancer Center, shared a post on X:
“Nice to see National Comprehensive Cancer Network (NCCN)
listing imlunestrant + abemaciclib as an option (with a footnote).
I’d consider this combo in ESR1 WT as well as ESR1-mut disease. Curious what others think.”
More posts featuring Abi Siva.